Yumi Iida

Suggest Changes
Learn More
BACKGROUND Cell-based therapies involving mononuclear cells (MNCs) have been developed for vascular regeneration to treat ischemic diseases; however, quality control of therapeutic MNCs has not been(More)
  • 1